RAF1 and neoplasm: As a result, αC-IN RAF inhibitors like AZ628 can hinder both BRAF and CRAF dimers, classifying them as ‘pan-RAF inhibitors,’ which may be particularly effective in RAF-mutant tumor cells where CRAF becomes the primary activator of ERK signaling [9,10].